You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 10,232,061

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,232,061

Title:	Freeze-dried formulation for gas-filled microvesicles
Abstract:	A freeze-dried powder composition comprising a phospholipid and a polyethylene glycol, said polyethylene glycol having a percentage of folded polymeric chains of 40% or higher. The composition is suitable for preparing gas-filled microvesicles.
Inventor(s):	Lassus; Anne (Veyrier, CH), Gorgerat; Stephane (Essertines-sur-Rolle, CH), Yan; Feng (Grand Lancy, CH), Guillot; Christian (Beaumont, FR), Brochot; Jean (Cruseilles, FR)
Assignee:	Bracco Suisse SA (Manno, CH)
Application Number:	16/028,536
Patent Claims:	1. A freeze-dried powder composition for the preparation of gas-filled microvesicles, said composition comprising a phospholipid and a polyethylene glycol, wherein said polyethylene glycol has a percentage of folded polymeric chains of from 40% to 80%. 2. The composition according to claim 1 wherein said percentage of folded chains is of at least 42%. 3. The composition according to claim 1 wherein said percentage of folded chains is of at least 44%. 4. The composition according to claim 1 wherein said polyethylene glycol is a PEG4000 having an average molecular weight in number (Mn) of from 4000 g/mol to 4600 g/mol. 5. The composition according to claim 4 wherein said Mn is of at least 4025 g/mol. 6. The composition according to claim 1 wherein said phospholipid is distearoylphosphatidyl-choline (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na) or a mixture thereof. 7. The composition according to claim 4 wherein said phospholipid is DSPC, DPPG-Na or a mixture thereof. 8. The composition according to claim 1 wherein said composition further comprises a fatty acid. 9. The composition according to claim 8 wherein said fatty acid is palmitic acid. 10. The composition according to claim 7 further comprising palmitic acid. 11. The composition of claim 10 comprising from 22 to 28 parts by weight of PEG4000, from 0.15 to 0.25 parts by weight of DSPC, from 0.15 to 0.25 parts by weight of DPPG-Na and from 0.02 to 0.06 parts by weight of palmitic acid. 12. The composition of claim 11 comprising 24.56 mg of PEG4000, 0.19 mg of DSPC, 0.19 mg of DPPG-Na and 0.04 mg of palmitic acid. 13. A sealed vial containing a freeze-dried powder composition according to claim 1 in contact with a physiologically acceptable gas. 14. A sealed vial containing a freeze-dried powder composition according to claim 11 in contact with a physiologically acceptable gas. 15. The sealed vial according to claim 13, wherein said gas is a fluorinated gas. 16. The sealed vial according to claim 14, wherein said gas is a fluorinated gas. 17. A method for manufacturing a lyophilized composition comprising a phospholipid and a polyethylene glycol, which comprises: a. dissolving said phospholipid and said polyethylene glycol in a solvent, thereby forming a solution; b. freezing the solution; and c. removing the solvent by lyophilization; wherein said polyethylene glycol has a percentage of folded polymeric chains of from 40% to 80%. 18. The method according to claim 17 wherein said phospholipid is DSPC, DPPG-Na or a mixture thereof. 19. The method according to claim 18 wherein said composition further comprises a fatty acid and said step a. comprises further dissolving said fatty acid in said solvent. 20. The method according to claim 19 wherein said composition comprises from 22 to 28 parts by weight of PEG4000, from 0.15 to 0.25 parts by weight of DSPC, from 0.15 to 0.25 parts by weight of DPPG-Na and from 0.02 to 0.06 parts by weight of palmitic acid. 21. A method for preparing a suspension of gas-filled microvesicles which comprises dispersing a freeze-dried powder composition according to claim 1, in the presence of a physiologically acceptable gas, in a physiologically acceptable liquid. 22. A method for preparing a suspension of gas-filled microvesicles which comprises dispersing a freeze-dried powder composition according to claim 11, in the presence of a physiologically acceptable gas, in a physiologically acceptable liquid. 23. The method according to claim 21 wherein said gas is sulfur hexafluoride. 24. The method according to claim 22 wherein said gas is sulfur hexafluoride.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.